Hodgkin Lymphoma (HL) Treatment and Our Challenges in Bangladesh

Authors

  • Abu Jafar Mohammed Saleh Evercare Hospital, Dhaka

DOI:

https://doi.org/10.37545/haematoljbd202176

Keywords:

Hodgkin Lymphoma, Challenges in Bangladesh

Author Biography

Abu Jafar Mohammed Saleh, Evercare Hospital, Dhaka

Executive Editor, Haematol J Bangladesh; Senior Consultant and Coordinator, Adult Haematology and BMT, Evercare Hospital, Basundhara R/A, Dhaka

References

Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol. 2012; 30:2183-2189

Chen, R. et al. Keynote. phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. J. Clin. Oncol. 35, 2125–2132 (2017).

Diefenbach CS, Hong F, Ambinder RF et al. Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial. Lancet Haematol. 2020; 7(9):E660-E670

Ramos CA, Bilgi M, Gerken C, et al. CD30-chimeric antigen receptor (CAR) T cells for therapy of Hodgkin lymphoma (HL). Abstract #79. Presented at the Transplantation & Cellular Therapy Meetings of ASBMT and CIBMTR, February 23, 2019; Houston, TX.

Grover NS, Park SI, Ivanova A, et al. A phase Ib/II study of anti-CD30 chimeric antigen receptor T cells for relapsed/refractory CD30+ lymphomas. Abstract #83. Presented at the Transplantation & Cellular Therapy Meetings of ASBMT and CIBMTR, February 23, 2019; Houston, TX.

Straus, D. J. et al. Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study. Blood 135, 735–742 (2020).

Ramchandren R, Fanale MA, Rueda A, et al. Nivolumab for Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma (cHL): Results from the Phase 2 Checkmate 205 Study. ASH 2017. Abstract 651.1.

Brockelman et al. Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma -The Randomized Phase 2 German Hodgkin Study Group NIVAHL Trial JAMA Oncol. 2020;6(6):872-880.

Moskowitz, C. H. et al. from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. Blood 132, 2639–2642 (2018)

Downloads

Published

06.05.2021 — Updated on 09.06.2021

How to Cite

1.
Saleh AJM. Hodgkin Lymphoma (HL) Treatment and Our Challenges in Bangladesh. Haematol J Bangladesh [Internet]. 2021 Jun. 9 [cited 2021 Oct. 19];5(01):01-2. Available from: https://journal.hematologybd.org/index.php/haematoljbd/article/view/76

Issue

Section

Editorial